Clinical Trials Logo

SCLC, Recurrent clinical trials

View clinical trials related to SCLC, Recurrent.

Filter by:
  • None
  • Page 1

NCT ID: NCT04525391 Terminated - SCLC, Recurrent Clinical Trials

AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer

SUKSES-N5
Start date: September 18, 2020
Phase: Phase 2
Study type: Interventional

Samsung Medical Centre, Seoul, Korea. Additional 0~5 Korea Lung Cancer Consortium (KLCC) centres in Korea Up to 40 subjects will be enrolled in two-stages (first stage: 19 evaluable subjects and second stage: 17 evaluable subjects and additional 4 subjects considering the drop out rate) If the study is conducted as de-escalated dosage (Durvalumab 1120mg) after the safety run-in, number of the patients will be counted from the second safety-run in phase.